Alterity, FDA agree on phase 3 program for multiple system atrophy asset ATH434
Seeking Alpha News (Tue, 9-Jun 7:34 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Tue, 9-Jun 7:17 AM ET)
Globe Newswire (Tue, 9-Jun 7:05 AM ET)
TipRanks (Tue, 9-Jun 6:29 AM ET)
Globe Newswire (Tue, 19-May 7:25 AM ET)
Globe Newswire (Mon, 11-May 7:25 AM ET)
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
Globe Newswire (Thu, 7-May 7:25 AM ET)
Alterity Therapeutics Releases Appendix 4C - Q3 FY26 Quarterly Cash Flow Report & Corporate Update
Globe Newswire (Thu, 30-Apr 7:25 AM ET)
Globe Newswire (Mon, 27-Apr 7:25 AM ET)
Globe Newswire (Wed, 22-Apr 7:25 AM ET)
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
Alterity Therapeutics Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol ATHE.
As of June 9, 2026, ATHE stock price climbed to $4.29 with 430,109 million shares trading.
ATHE has a beta of 2.49, meaning it tends to be more sensitive to market movements. ATHE has a correlation of 0.20 to the broad based SPY ETF.
ATHE has a market cap of $77.76 million. This is considered a Micro Cap stock.
In the last 3 years, ATHE traded as high as $7.00 and as low as $1.00.
ATHE has underperformed the market in the last year with a return of -11.4%, while SPY returned +24.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ATHE shares. However, ATHE has outperformed the market in the last 3 month and 2 week periods, returning +20.8% and +5.1%, while SPY returned +8.9% and -1.8%, respectively. This indicates ATHE has been having a stronger performance recently.
ATHE support price is $3.70 and resistance is $4.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATHE shares will trade within this expected range on the day.